EHAB (Enhabit) GF Value Rank : 8 (As of Apr. 23, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Enhabit GF Value Rank?

Enhabit has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Enhabit's GF Value Rank

For the Medical Care Facilities subindustry, Enhabit's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enhabit's GF Value Rank Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Enhabit's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Enhabit's GF Value Rank falls into.

Save Embed

;

Save Embed

;

Enhabit GF Value Rank Related Terms

Thank you for viewing the detailed overview of Enhabit's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Enhabit Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Enhabit Inc (NYSE:EHAB) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

X34:Germany

Address

6688 N. Central Expressway, Suite 1300, Dallas, TX, USA, 75206

Website

https://www.ehab.com

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

Executives

Jeffrey Bolton	director	1016 CIVIC CENTER DRIVE NW, ROCHESTER MN 55901
Stuart M Mcguigan	director	74 AGAMENTICUS AVENUE, CAPE NEDDICK ME 03902
Erin Hoeflinger	director	511 FALLVIEW COURT, SPRINGBORO OH 45066
Langham Ronald Leroy Jr	officer: EVP Clinical Excel. & Strategy	6688 CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Shaw L Edward Jr	director	AETNA INC, 151 FARMINGTON AVE RC4B, HARTFORD CT 06156
Barry P. Schochet	director	100 EAST RIVERCENTER BLVD, 16TH FLOOR, COVINGTON KY 41011
Dylan C Black	officer: General Counsel and Secretary	6688 CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Higdon Leo I Jr	director	1700 LINCOLN STREET, 28TH FLOOR, DENVER CO 80203
Gregory S Rush	director	TEKELEC, 26580 W. AGOURA RD., CALABASAS CA 91302
Tina L. Brown-stevenson	director	6688 N. CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Tanya Renee Marion	officer: Chief Human Resources Officer	6688 NORTH CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Charles M Elson	director	1401 61STG STREET S, STETSON UNIV COLLEGE OF LAW, ST PETERSBURG FL 33707
Barbara Ann Jacobsmeyer	director, officer: President and CEO	2122 ACTON PARK WAY, BIRMINGHAM AL 35243
Yvonne M Curl	director	C/O ENHABIT, INC., 6688 N. CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Maupin John E Jr D D S	director	103 POWELL COURT SUITE 200, BRENTWOOD TN 37027